A peroxisome proliferator-activated receptor-δ agonist provides neuroprotection in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson’s disease
Open Access
- 1 June 2013
- journal article
- Published by Elsevier in Neuroscience
- Vol. 240, 191-203
Abstract
No abstract availableKeywords
This publication has 50 references indexed in Scilit:
- Pharmacological manipulation of peroxisome proliferator-activated receptor γ (PPARγ) reveals a role for anti-oxidant protection in a model of Parkinson's diseaseExperimental Neurology, 2012
- PPAR‐gamma‐mediated neuroprotection in a chronic mouse model of Parkinson’s diseaseEuropean Journal of Neuroscience, 2009
- Rosiglitazone reverses memory decline and hippocampal glucocorticoid receptor down-regulation in an Alzheimer’s disease mouse modelBiochemical and Biophysical Research Communications, 2009
- PPARγ agonist rosiglitazone is neuroprotective after traumatic brain injury via anti-inflammatory and anti-oxidative mechanismsBrain Research, 2008
- PPARδ Is a Type 1 IFN Target Gene and Inhibits Apoptosis in T CellsJournal of Investigative Dermatology, 2008
- Correlation of mRNA and protein levels: Cell type-specific gene expression of cluster designation antigens in the prostateBMC Genomics, 2008
- Lipid-lowering drugs in the MPTP mouse model of Parkinson's disease: Fenofibrate has a neuroprotective effect, whereas bezafibrate and HMG-CoA reductase inhibitors do notBrain Research, 2007
- Protocol for the MPTP mouse model of Parkinson's diseaseNature Protocols, 2007
- Roles of PPAR delta in lipid absorption and metabolism: a new target for the treatment of type 2 diabetesBiochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 2005
- Interleukin-1β, interleukin-6, epidermal growth factor and transforming growth factor-α are elevated in the brain from parkinsonian patientsNeuroscience Letters, 1994